Baricitinib

Target: This ligand targets Janus kinases JAK1 and JAK2 in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for Janus kinases JAK1 and JAK2. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings Janus kinases JAK1 into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Design for JAK1/2: Baricitinib can be used as a kinase-binding ligand to construct PROTACs that recruit E3 ligases and drive selective degradation of JAK1 and/or JAK2. This enables functional interrogation of cytokine signaling by reducing target protein abundance rather than only inhibiting kinase activity, improving mechanistic clarity in pathway studies.

• E3 Ligase Recruitment Optimization: Incorporating baricitinib into PROTAC scaffolds allows systematic screening of linker length, attachment position, and E3 ligase ligands to maximize ternary complex formation and ubiquitination efficiency. Such optimization supports identification of degradation-competent constructs that yield robust target knockdown across relevant cellular contexts.

• Pathway Degradation Versus Inhibition: PROTACs built with baricitinib can distinguish degradation-driven phenotypes from conventional JAK inhibition. By comparing downstream STAT phosphorylation, cytokine-responsive transcription, and compensatory signaling, researchers can quantify how loss of JAK protein influences signaling dynamics, duration, and resistance mechanisms.

• Mechanistic Studies of Resistance: Baricitinib-based PROTACs can be applied to evaluate whether targeted degradation mitigates resistance observed with catalytic inhibitors. Monitoring changes in JAK stability, ubiquitin engagement, and signaling output under perturbation helps define degradation efficacy under stress conditions and informs next-generation PROTAC design strategies.

• Target Engagement and Biomarker Discovery: Using baricitinib as the targeting element, PROTAC experiments can map degradation kinetics and establish biomarkers linked to JAK protein turnover. Time-course analyses of target levels and pathway readouts support selection of informative assays for studying ubiquitin-proteasome engagement and for comparing construct performance across cell types.

Baricitinib is a JAK inhibitor scaffold that can inform JAK-directed PROTAC design. A linker-ready analog is preferred because the parent molecule lacks a direct free coupling handle.

Structure: Baricitinib is a JAK inhibitor containing a pyrrolopyrimidine-pyrazole kinase-binding core, an azetidine sulfonamide, and an acetonitrile side chain. The molecule is compact and polar and contains a constrained azetidine bearing a sulfonyl substituent.

Reactivity: Baricitinib-derived PROTAC design should preserve the pyrrolopyrimidine-pyrazole core required for JAK recognition. Linker vectors may be explored from the azetidine sulfonamide or acetonitrile-adjacent side chain in designed analogs rather than directly modifying the heteroaryl core. Alkyl, PEG, amide, sulfonamide, or carbamate linkers may be coupled to CRBN, VHL, or IAP ligands, but a linker-ready derivative is needed because the parent lacks a free coupling handle.